Numerous clinical trials have shown that SGLT2 inhibitors have potent cardioprotective effects, which in turn reduces cardiovascular adverse events, including heart failure hospitalizations and cardiovascular mortality (7–11, 21, 22). This evidence concerns the gene SLC5A2 and heart failure.